Hypoxia-inducible factors in cancer stem cells and inflammation
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Hypoxia-inducible factors (HIF) mediate metabolic switch in cells in hypoxic environments, including those in both normal and malignant tissues with limited supplies of oxygen. Paradoxically, recent studies have shown that cancer stem cells and activated immune effector cells exhibit high HIF activity in normoxic environments and that HIF activity is critical in maintenance of cancer stem cells as well as differentiation and function of inflammatory cells. Since inflammation and cancer stem cells are two major barriers to effective cancer therapy, targeting HIF may provide a new approach for the ultimate challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783 · cited 3×
“Historically, prospective identification of AML stem cells by John Dick and colleagues in 1994 marked the revival of the cancer stem cell concept [4].”
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · cited 9×
“Two reports suggested that IDH mutations lead to increase in HIF-1α accumulation [25, 26], while a more recent study suggests otherwise [32].”
InfluentialSelf-citationNoman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892 · cited 1×
“Fourth, NPM1 is mutated in 30–40% of AML samples that have a normal karyotype [108, 109].”
Shi, L. Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D. R., & Chi, H. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110278 · Cited by 1,803
Cited by
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962
ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance
Begicevic, R.-R., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112362 · Cited by 395
Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications
Nazio, F., Bordi, M., Cianfanelli, V., Locatelli, F., & Cecconi, F. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-019-0292-y · Cited by 388
Cancer stem cells: The root of tumor recurrence and metastases
Peitzsch, C., Tyutyunnykova, A., Pantel, K., & Dubrovska, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.011 · Cited by 372
HIF-1 in cancer therapy: two decade long story of a transcription factor
Soni, S., & Padwad, Y. S. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1301680 · Cited by 251
Bailey, C. M., Liu, Y., Liu, M., Du, X., Devenport, M., Zheng, P., Liu, Y., & Wang, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150846 · Cited by 151
Self-citationRychtarcikova, Z., Lettlova, S., Tomkova, V., Korenkova, V., Langerova, L., Simonova, E., Zjablovskaja, P., Alberich-Jorda, M., Neuzil, J., & Truksa, J. (2017) · Oncotarget · doi:10.18632/oncotarget.14093 · Cited by 100
Vahidian, F., Duijf, P. H. G., Safarzadeh, E., Derakhshani, A., Baghbanzadeh, A., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.004 · Cited by 75
Organotypic 3D decellularized matrix tumor spheroids for high-throughput drug screening
Ferreira, L. P., Gaspar, V. M., Mendes, L., Duarte, I. F., & Mano, J. F. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120983 · Cited by 59
“In vivo solid tumor masses are characterized by restrictions in the diffusion of nutrients and oxygen, promoting altered metabolic profiles [62], and hypoxia [63], that culminate with the appearance of necrotic regions.”
BackgroundHypoxia-induced cancer cell reprogramming: a review on how cancer stem cells arise
Abd, G. M., Laird, M. C., Ku, J. C., & Li, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1227884 · Cited by 41
“All three heterodimerize with the HIF-1b subunit and are subject to posttranslational regulation that is dependent on oxygen levels in the environment (52).”
BackgroundAssociations between HIFs and tumor immune checkpoints: mechanism and therapy
Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-023-00836-7 · Cited by 13
“Importantly, HIF suppression is a topic of ongoing research in cancer treatment [6, 102].”
Background
Metadata
- Authors
- Peng, G., & Liu, Y.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 36
- Issue
- 6
- Pages
- 374-383
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2047057500
- Cited by
- 123
- References
- 49
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.